Industry & Policy News

[Palisade Bio, Inc.] Palisade Bio, Inc. announced that the US FDA has cleared the Company’s Investigational New Drug (IND) application for PALI-2108, enabling initiation of the Phase 2 ASCENTRA-CD clinical trial in patients with moderate to severe Crohn’s disease.

[Prostate Cancer Foundation (BusinessWire)] The Prostate Cancer Foundation will convene leading researchers, clinicians and industry experts at its 33rd Annual Scientific Retreat. The Retreat is the world’s foremost scientific conference on prostate cancer biology and treatment.

[Nevada Today] A new seed-grant fund established in collaboration with Renown Health’s William N. Pennington Cancer Institute (PCI) has awarded more than $667,000 to researchers, including Dr. Dean Burkin to study a small molecule which could be useful as a treatment modality for prostate cancer.

[Weill Cornell Medicine] Weill Cornell Medicine has received major new funding to support collaborative research, including a $2 million grant to Dr. Scott Tagawa from the Department of Defense to lead Weill Cornell Medicine and NewYork-Presbyterian’s participation in the Prostate Cancer Clinical Trials Consortium.

[Bayer] Bayer announced that the US FDA has accepted the company’s supplemental new drug application (sNDA) and granted Priority Review designation for Lynkuet™ (elinzanetant) for the treatment of moderate to severe vasomotor symptoms in women receiving endocrine therapy for the treatment or prevention of hormone receptor positive breast cancer.

[Flatiron Health] Flatiron Health announced that its Breast Cancer Panoramic dataset has surpassed one million patients — the largest rigorously curated breast cancer real-world dataset of its kind.